Concluded an investigator initiated trial agreement with National Cancer Center Hospital East for Telomelysin (OBP-301) combined with other therapies.
Concluded an investigator-initiated trial agreement with National Cancer Center Hospital East for Telomelysin (OBP-301) combined with other therapies.